We have decades of experience in analyzing small and mid-cap stocks as well as disseminating this information to retail investors. With investment cases, we provide free information on investment opportunities within the segment of Nordic small and mid-caps companies for primarily a Nordic investing audience.
If you want to contact us directly, find contact details for the individual employee under Line Up.
Last week saw no major changes at index level, with the Nordic growth exchanges unchanged. However, there are always opportunities
Nexcom maintains a revenue in the level of DKK 11-15 million and EBITDA in the level of (2) – 1.5
Last week, the Nordic growth stock markets fell, while the major indices continued their price increases in 2023. The week’s
In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established
CS Medica has achieved positive results of a clinical study with its pain patch with CBD. With clinical proof of
The Q3 report (January-March 2023) from Mdundo shows a high user growth to 24.5 million monthly active users, which has
The 2022 annual report from EKOBOT is without information that can have a significant price impact and after the recent
Biosergen: 1.5 million people die each year from fungal infections. Biosergen, which has FDA orphan drug status, is developing an
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.